Amalgamated Bank Sells 951 Shares of Hologic, Inc. (NASDAQ:HOLX)

Amalgamated Bank reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,583 shares of the medical equipment provider’s stock after selling 951 shares during the quarter. Amalgamated Bank’s holdings in Hologic were worth $3,214,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of HOLX. RWC Asset Management LLP grew its position in Hologic by 13.0% during the 4th quarter. RWC Asset Management LLP now owns 2,971 shares of the medical equipment provider’s stock worth $214,000 after acquiring an additional 342 shares during the last quarter. Capital Investment Counsel Inc grew its holdings in shares of Hologic by 3.6% in the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock worth $413,000 after purchasing an additional 200 shares during the last quarter. Handelsbanken Fonder AB increased its stake in shares of Hologic by 8.2% in the fourth quarter. Handelsbanken Fonder AB now owns 214,233 shares of the medical equipment provider’s stock worth $15,444,000 after buying an additional 16,262 shares during the period. Private Advisor Group LLC raised its holdings in Hologic by 7.7% during the 4th quarter. Private Advisor Group LLC now owns 17,931 shares of the medical equipment provider’s stock valued at $1,293,000 after buying an additional 1,278 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in Hologic by 15.5% during the 4th quarter. Global Retirement Partners LLC now owns 2,175 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 292 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is owned by company insiders.

Analyst Ratings Changes

HOLX has been the topic of a number of analyst reports. Wolfe Research started coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Stephens restated an “overweight” rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a report on Monday, February 3rd. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $85.77.

Hologic Trading Up 0.3 %

Shares of NASDAQ HOLX opened at $63.38 on Friday. Hologic, Inc. has a 1 year low of $62.69 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a 50-day moving average of $69.16 and a 200 day moving average of $75.94. The stock has a market cap of $14.22 billion, a P/E ratio of 19.99, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.